Evidence map›Paper›PMID 34557016›Full record

ArticleJournal of inflammation research2021

Biotite-Calx Based Traditional Indian Medicine

Acharya Balkrishna, Siva Kumar Solleti, Hoshiyar Singh, Rani Singh, Niti Sharma, Anurag Varshney

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Acharya BalkrishnaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Siva Kumar Solleti *Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Hoshiyar Singh *Drug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Rani SinghDrug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Niti SharmaDrug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.
Anurag VarshneyDrug Discovery and Development Division, Patanjali Research Institute, Haridwar, Uttarakhand, India.ORCID 0000-0001-8509-0882
Patanjali Research Foundation · INJawaharlal Nehru University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAsthma is a heterogeneous airway inflammatory disease with limited therapeutic options. Traditional medicine is extensively used for treating various ailments including asthma.

methodsWe have tested for the anti-inflammatory and anti-asthmatic properties of SPAB, using a mouse model of ovalbumin-induced allergic asthma in-vivo and cell-based assays in-vitro. Histological analysis, qPCR and ELISA were performed to assess the pathology. SEM, EDX and XRD-analysis were performed to characterize the SPAB particles.

resultsSEM, EDX and XRD-analysis identified the presence of SPAB particle of 100 nm-~1µm diameter and contains annite-1M, aluminium silicate, kyanite, aluminium oxide, magnesium silicate, and maghemite in the samples. Ova-challenge resulted in severe inflammatory responses, airway remodelling and increased oxidative burden in lungs. Importantly, prophylactic treatment with SPAB significantly attenuated allergen induced leukocyte infiltration specifically eosinophils, lymphocytes, macrophages and neutrophils in BALF. Ova-induced mucus hypersecretion, peri-bronchial collagen deposition, inflammatory cell infiltration and bronchial epithelial thickening were significantly abrogated upon SPAB treatment. qPCR and ELISA analysis identified that allergen induced increases in

conclusionTaken together, our results experimentally validated the prophylactic ameliorative potential of the Indian classical medicine

Indexed as

asthmacytokinelung inflammationmica-medicinephysicochemical analysisSahastraputi-Abhrak-Bhasma

Identifiers

PMID34557016
PMCPMC8455516
OpenAlexW3201147319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.